Testing a new prostate cancer screening pathway using MRI and a risk calculator
Tests a screening pathway using blood tests and MRI in men aged 55 to 65.
Key facts
- Who runs it
- Fondazione del Piemonte per l'Oncologia
- Where
- Candiolo, ItalySee the site
- Trial code
- Registry title
- Prostate Cancer Screening: a Pilot Study
- Status
- Enrolling by invitation
- People taking part
- 4,500 people, planned
- Started
- 17 Feb 2025
- Planned end
- 30 Jun 2026
- Type of study
- Interventional
- Treatments tested
- Urology visit with Risk Calculator and MRI
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 55 to 65 with no or few urinary symptoms. They must live in the ASL TO5 area (Piedmont, Italy) and have had no prostate biopsy.
- Age
- 55 to 65 years
- Sex
- Men only
- Earlier treatment
- No previous prostate biopsy. No previous radiotherapy of the pelvis.
Main reasons for not taking part
- Previous prostate cancer
- Previous prostate biopsy or prostate surgery
- Previous radiotherapy of the pelvis
- Any reason that rules out an MRI scan
- Claustrophobia or being unable to cooperate
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- age between 55-65 years
- asymptomatic or paucisymptomatic from a urological point of view
- no previous prostate biopsy
- living in the ASL TO5 (Piedmont, Italy)
- signed written informed consent
Who cannot take part
- previous biopsy or prostate surgery
- previous radiotherapy of the pelvis
- positive oncologic anamnesis for prostate cancer
- any contraindication to MRI examination
- claustrophobic or uncollaborative subjects
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 65 years old?
Where in Italy
- Fondazione del Piemonte per l'OncologiaCandiolo, ItalyNo longer taking part
About the trial
What the trial wants to find out
Prostate Cancer (PCa) is the second most frequently diagnosed tumour and the third most lethal among men in Europe. The lack of precise tools and examinations to precisely diagnose PCa has caused overtreatment of indolent and low-aggressive PCa, while in some other cases, with aggressive disease, diagnosis and treatment are dangerously delayed because cancer could be potentially missed. The present trial aims to study a new pathway to early diagnose PCa with Magnetic Resonance Imaging (MRI) to identify men who will not need treatment and those who will benefit from radical treatment, thus improving disease control and quality of life.
The group in the trial
- Subjects with PSA ≥ 3 ng/mlTreatment being tested
* Urologic examination * Risk calculation (ERSPC no.6) * Magnetic resonance imaging * (optional) biopsy
Treatment: Urology visit with Risk Calculator and MRI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prostate Cancer Screening With PSA, Risk Calculator and Multiparametric MRI: a Pilot Study
- Plain-language title
- Testing a new prostate cancer screening pathway using MRI and a risk calculatorGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06238661, who can take part
- Record updated
- 5 March 2026